The impact of Onco type DX® recurrence score of paraffin-embedded core biopsy tissues in predicting response to neoadjuvant chemotherapy in women with breast cancer

Atilla Soran, Rohit Bhargava, Ronald Johnson, Gretchen Ahrendt, Marguerite Bonaventura, Emilia Diego, Priscilla F. McAuliffe, Merida Serrano, Ebru Menekse, Efe Sezgin, Kandace P. McGuire

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Oncotype DX® test is beneficial in predicting recurrence free survival in estrogen receptor positive (ER+) breast cancer. Ability of the assay to predict response to neoadjuvant chemotherapy (NCT) is less well-studied. OBJECTIVE: We hypothesize a positive association between the Oncotype DX® recurrence score (RS) and the percentage tumor response (%TR) after NCT. METHODS: Pre-therapy RS was measured on core biopsies from 60 patients with ER+, HER2.. invasive breast cancer (IBC) who then received NCT. Pre-therapy tumor size was measured using imaging. %TR, partial response (PR; 50%), pathologic complete response (PCR) and breast conserving surgery (BCS) rates were measured. RESULTS: Median RS was 20 (2 69). Median %TR was 42 (0 97)%. PR was observed in 43% of patients. There was no association between %TR and pre-NCT tumor size, age, Nottingham score or nodal status (p 0:05). No statistically significant association with %TR was seen with RS as a categorical or continuous variable (p = 0:21 and 0.7, respectively). Response to NCT improved as ER (p = 0:02) by RT-PCR decreased. Lower ER expression by IHC correlated with response (p = 0:03). CONCLUSIONS: In patients with ER+ IBC receiving NCT, RS did not predict response to NCT using %TR. The benefit of the assay prior to NCT requires further study.

Original languageEnglish (US)
Pages (from-to)65-71
Number of pages7
JournalBreast Disease
Volume36
Issue number2-3
DOIs
StatePublished - 2016
Externally publishedYes

Fingerprint

Paraffin
Breast Neoplasms
Biopsy
Recurrence
Drug Therapy
Neoplasms
Segmental Mastectomy
Estrogen Receptors
Survival
Therapeutics

Keywords

  • 21 gene assay
  • breast cancer
  • Estrogen positive
  • neoadjuvant
  • response
  • tumor volume reduction

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

The impact of Onco type DX® recurrence score of paraffin-embedded core biopsy tissues in predicting response to neoadjuvant chemotherapy in women with breast cancer. / Soran, Atilla; Bhargava, Rohit; Johnson, Ronald; Ahrendt, Gretchen; Bonaventura, Marguerite; Diego, Emilia; McAuliffe, Priscilla F.; Serrano, Merida; Menekse, Ebru; Sezgin, Efe; McGuire, Kandace P.

In: Breast Disease, Vol. 36, No. 2-3, 2016, p. 65-71.

Research output: Contribution to journalArticle

Soran, A, Bhargava, R, Johnson, R, Ahrendt, G, Bonaventura, M, Diego, E, McAuliffe, PF, Serrano, M, Menekse, E, Sezgin, E & McGuire, KP 2016, 'The impact of Onco type DX® recurrence score of paraffin-embedded core biopsy tissues in predicting response to neoadjuvant chemotherapy in women with breast cancer', Breast Disease, vol. 36, no. 2-3, pp. 65-71. https://doi.org/10.3233/BD-150199
Soran, Atilla ; Bhargava, Rohit ; Johnson, Ronald ; Ahrendt, Gretchen ; Bonaventura, Marguerite ; Diego, Emilia ; McAuliffe, Priscilla F. ; Serrano, Merida ; Menekse, Ebru ; Sezgin, Efe ; McGuire, Kandace P. / The impact of Onco type DX® recurrence score of paraffin-embedded core biopsy tissues in predicting response to neoadjuvant chemotherapy in women with breast cancer. In: Breast Disease. 2016 ; Vol. 36, No. 2-3. pp. 65-71.
@article{60bf5ef969f4477db98996a028430e1b,
title = "The impact of Onco type DX{\circledR} recurrence score of paraffin-embedded core biopsy tissues in predicting response to neoadjuvant chemotherapy in women with breast cancer",
abstract = "BACKGROUND: Oncotype DX{\circledR} test is beneficial in predicting recurrence free survival in estrogen receptor positive (ER+) breast cancer. Ability of the assay to predict response to neoadjuvant chemotherapy (NCT) is less well-studied. OBJECTIVE: We hypothesize a positive association between the Oncotype DX{\circledR} recurrence score (RS) and the percentage tumor response ({\%}TR) after NCT. METHODS: Pre-therapy RS was measured on core biopsies from 60 patients with ER+, HER2.. invasive breast cancer (IBC) who then received NCT. Pre-therapy tumor size was measured using imaging. {\%}TR, partial response (PR; 50{\%}), pathologic complete response (PCR) and breast conserving surgery (BCS) rates were measured. RESULTS: Median RS was 20 (2 69). Median {\%}TR was 42 (0 97){\%}. PR was observed in 43{\%} of patients. There was no association between {\%}TR and pre-NCT tumor size, age, Nottingham score or nodal status (p 0:05). No statistically significant association with {\%}TR was seen with RS as a categorical or continuous variable (p = 0:21 and 0.7, respectively). Response to NCT improved as ER (p = 0:02) by RT-PCR decreased. Lower ER expression by IHC correlated with response (p = 0:03). CONCLUSIONS: In patients with ER+ IBC receiving NCT, RS did not predict response to NCT using {\%}TR. The benefit of the assay prior to NCT requires further study.",
keywords = "21 gene assay, breast cancer, Estrogen positive, neoadjuvant, response, tumor volume reduction",
author = "Atilla Soran and Rohit Bhargava and Ronald Johnson and Gretchen Ahrendt and Marguerite Bonaventura and Emilia Diego and McAuliffe, {Priscilla F.} and Merida Serrano and Ebru Menekse and Efe Sezgin and McGuire, {Kandace P.}",
year = "2016",
doi = "10.3233/BD-150199",
language = "English (US)",
volume = "36",
pages = "65--71",
journal = "Breast Disease",
issn = "0888-6008",
publisher = "IOS Press",
number = "2-3",

}

TY - JOUR

T1 - The impact of Onco type DX® recurrence score of paraffin-embedded core biopsy tissues in predicting response to neoadjuvant chemotherapy in women with breast cancer

AU - Soran, Atilla

AU - Bhargava, Rohit

AU - Johnson, Ronald

AU - Ahrendt, Gretchen

AU - Bonaventura, Marguerite

AU - Diego, Emilia

AU - McAuliffe, Priscilla F.

AU - Serrano, Merida

AU - Menekse, Ebru

AU - Sezgin, Efe

AU - McGuire, Kandace P.

PY - 2016

Y1 - 2016

N2 - BACKGROUND: Oncotype DX® test is beneficial in predicting recurrence free survival in estrogen receptor positive (ER+) breast cancer. Ability of the assay to predict response to neoadjuvant chemotherapy (NCT) is less well-studied. OBJECTIVE: We hypothesize a positive association between the Oncotype DX® recurrence score (RS) and the percentage tumor response (%TR) after NCT. METHODS: Pre-therapy RS was measured on core biopsies from 60 patients with ER+, HER2.. invasive breast cancer (IBC) who then received NCT. Pre-therapy tumor size was measured using imaging. %TR, partial response (PR; 50%), pathologic complete response (PCR) and breast conserving surgery (BCS) rates were measured. RESULTS: Median RS was 20 (2 69). Median %TR was 42 (0 97)%. PR was observed in 43% of patients. There was no association between %TR and pre-NCT tumor size, age, Nottingham score or nodal status (p 0:05). No statistically significant association with %TR was seen with RS as a categorical or continuous variable (p = 0:21 and 0.7, respectively). Response to NCT improved as ER (p = 0:02) by RT-PCR decreased. Lower ER expression by IHC correlated with response (p = 0:03). CONCLUSIONS: In patients with ER+ IBC receiving NCT, RS did not predict response to NCT using %TR. The benefit of the assay prior to NCT requires further study.

AB - BACKGROUND: Oncotype DX® test is beneficial in predicting recurrence free survival in estrogen receptor positive (ER+) breast cancer. Ability of the assay to predict response to neoadjuvant chemotherapy (NCT) is less well-studied. OBJECTIVE: We hypothesize a positive association between the Oncotype DX® recurrence score (RS) and the percentage tumor response (%TR) after NCT. METHODS: Pre-therapy RS was measured on core biopsies from 60 patients with ER+, HER2.. invasive breast cancer (IBC) who then received NCT. Pre-therapy tumor size was measured using imaging. %TR, partial response (PR; 50%), pathologic complete response (PCR) and breast conserving surgery (BCS) rates were measured. RESULTS: Median RS was 20 (2 69). Median %TR was 42 (0 97)%. PR was observed in 43% of patients. There was no association between %TR and pre-NCT tumor size, age, Nottingham score or nodal status (p 0:05). No statistically significant association with %TR was seen with RS as a categorical or continuous variable (p = 0:21 and 0.7, respectively). Response to NCT improved as ER (p = 0:02) by RT-PCR decreased. Lower ER expression by IHC correlated with response (p = 0:03). CONCLUSIONS: In patients with ER+ IBC receiving NCT, RS did not predict response to NCT using %TR. The benefit of the assay prior to NCT requires further study.

KW - 21 gene assay

KW - breast cancer

KW - Estrogen positive

KW - neoadjuvant

KW - response

KW - tumor volume reduction

UR - http://www.scopus.com/inward/record.url?scp=84988632525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988632525&partnerID=8YFLogxK

U2 - 10.3233/BD-150199

DO - 10.3233/BD-150199

M3 - Article

C2 - 27662272

AN - SCOPUS:84988632525

VL - 36

SP - 65

EP - 71

JO - Breast Disease

JF - Breast Disease

SN - 0888-6008

IS - 2-3

ER -